Login
$SPRB
$42.25 -$1.06 (2.45%) Live

Company Executives

Officer Age In this role 2025 pay Source
Javier Szwarcberg, M.D., MPH Also a director
Chief Executive Officer and Director
56 Not stated $2,910,573
Samir Gharib
President and Chief Financial Officer
43 Not stated $1,473,211
Michael Grey Also a director
Executive Chairman
Title from the Form 4 dated May 21, 2026
73 Not stated Not reported
Kirk Ways, M.D., Ph.D. Also a director
Interim Chief Medical Officer
74 Not stated $1,044,412
Corwin Dale Hooks
Chief Commercial Officer
59 Since 2026
this year
Not reported
Adrian Quartel
Chief Medical Officer
Title from the Form 8-K dated Jul 27, 2026
Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
4 of 7
stated in the proxy
Average tenure
4.7 years
from year joined
CEO also chairs the board
No
Michael Grey
Director Age On board Independent Committees Other public boards 2025 pay Source
Michael Grey
73 Not stated Not independent None stated None stated $79,940
Javier Szwarcberg
56 2022
4 years
Not independent None stated None stated Paid as CEO
Kirk Ways
74 2021
5 years
Not independent None stated None stated Not stated
Camilla V. Simpson
54 2017
9 years
Independent None stated GRI Bio, Inc. Not stated
Keli Walbert
59 2025
1 year
Independent
Compensation
Apellis Pharmaceuticals, Inc. $295,004
Percival Barretto-Ko
53 2023
3 years
Independent
Audit
None stated $52,056
Daniel Spiegelman
67 2020
6 years
Independent
Audit · Chair
Maze Therapeutics, Inc. $66,043

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

1 disclosed in the proxy filed Apr 9, 2026
Kirk Ways, M.D., Ph.D.
a director and current Interim Chief Medical Officer
$608,313
Since January 1, 2024

Consulting agreement under which Dr. Ways provides advisory services as Interim Chief Medical Officer; company paid him for services.

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support